InspireMD Ltd.
321 Columbus Avenue
Boston
Massachusetts
02116
Tel: 857-305-2410
Website: http://www.inspire-md.com/
Email: info@inspire-md.com
196 articles about InspireMD Ltd.
-
InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
3/6/2024
InspireMD, Inc., developer of the CGuard™ Embolic Prevention System for the treatment of carotid artery disease and prevention of stroke, announced financial and operating results for the fourth quarter and full-year ended December 31, 2023.
-
InspireMD to Report Fourth Quarter and Full-Year 2023 Financial Results and Provide Corporate Business Update on Wednesday, March 6th
2/28/2024
InspireMD, Inc. announced it will report fourth quarter and full-year 2023 financial results on Wednesday, March 6th, 2024, before the financial markets open.
-
InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard™ Neuroprotection System
2/12/2024
InspireMD, Inc. today announced that the Company has appointed principal investigators (PIs) for its upcoming C-GUARDIANS II clinical trial of the SwitchGuard™ Neuroprotection System (NPS).
-
InspireMD Announces Appointment of Medical Technology Executive Pete Ligotti as Executive Vice President and General Manager of North America
1/3/2024
InspireMD announced the appointment of medical technology executive Pete Ligotti as Executive Vice President and General Manager of North America.
-
InspireMD Announces Issuance of Key U.S. Patent Covering Its SwitchGuard™ Neuroprotection System
12/20/2023
InspireMD, developer of the CGuard™ Embolic Prevention Stent System for the prevention of stroke, announced the issuance of U.S. Patent No. 11,844,893, titled, “Shunts with Blood Flow Indicators.”.
-
InspireMD Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of CGuard EPS for the Treatment of Acute Stroke Patients with Tandem Lesions
11/27/2023
InspireMD Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of CGuard EPS for the Treatment of Acute Stroke Patients with Tandem Lesions.
-
InspireMD Reports Third Quarter 2023 Financial Results and Provides Business Update
11/6/2023
InspireMD, Inc., developer of the CGuard™ Embolic Prevention Stent System for treatment of carotid artery disease and prevention of stroke announced financial results and business updates for the third quarter ended September 30, 2023.
-
InspireMD to Participate in Upcoming November Investor Conferences
11/2/2023
InspireMD, Inc. today announced that the Marvin Slosman, Chief Executive Officer, will participate in three upcoming investor conferences in November.
-
InspireMD Supports CMS’ Final National Coverage Determination (NCD) Expanding Coverage of Carotid Stenting (CAS) to Include Both Asymptomatic and Standard Risk Patients
10/12/2023
InspireMD, Inc., developer of the CGuard™ Embolic Prevention Stent System for the prevention of stroke, announced its support for the Centers for Medicare and Medicaid Services final National Coverage Determination which expands coverage of carotid artery stenting and transcarotid artery revascularization to include both asymptomatic and standard risk patients.
-
InspireMD Announces Senior Leadership Changes to Support Commercial Growth Initiatives
10/3/2023
InspireMD, Inc. announced senior leadership additions and changes intended to support the company’s commercial growth initiatives, including potential approval of the CGuard Prime stent platform in the U.S., development of new stent delivery systems, and growth in existing approved territories outside of the U.S.
-
InspireMD Reports Second Quarter 2023 Financial Results and Provides Business Update
8/8/2023
InspireMD, Inc., developer of the CGuard™ Embolic Prevention Stent System for treatment of carotid artery disease and prevention of stroke announced financial and operating results for the second quarter ended June 30, 2023.
-
InspireMD to Report Second Quarter 2023 Financial Results and Provide Corporate Business Update on Tuesday, August 8th
7/25/2023
InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will report second quarter 2023 financial results on Tuesday, August 8thth, 2023, before the financial markets open.
-
InspireMD Announces Completion of Enrollment in C-Guardians U.S. Investigational Device Exemption (IDE) Clinical Trial
6/26/2023
InspireMD, Inc., developer of the CGuard™ Embolic Prevention Stent System for the prevention of stroke, announced that it completed enrollment of its ongoing C-Guardians U.S. Investigational Device Exemption clinical trial, designed to support potential U.S. marketing approval of the CGuard Prime EPS stent system.
-
InspireMD Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - May 18, 2023
5/18/2023
InspireMD, Inc. announced that, in connection with the appointment of Shane Gleason as General Manager of North America and VP of Global Marketing in February 2023, InspireMD granted Mr. Gleason 256,450 shares of restricted stock and stock options to purchase 85,480 shares of InspireMD’s common stock.
-
InspireMD Announces Private Placement of Up to $113.6 Million
5/15/2023
InspireMD, Inc. announced that the Company has signed a securities purchase agreement with certain healthcare-focused institutional investors that have agreed to provide up to $113.6 million in gross proceeds to InspireMD through a private placement that includes initial upfront funding of $42.2 million.
-
InspireMD Announces May 16, 2023 as New Date for First Quarter 2023 Results Conference Call and Webcast
5/12/2023
InspireMD, Inc. announced that it will host its conference call and webcast to review first quarter 2023 financial and operating results on Tuesday, May 16th, 2023, before the markets open.
-
InspireMD Announces May 15th as New Date for First Quarter 2023 Financial Results and Corporate Business Update
5/5/2023
InspireMD, Inc. announced it will now report first quarter 2023 financial results on Monday, May 15th, 2023.
-
InspireMD Announces Successful First-in-Human Procedure Utilizing CGuard Prime, its Next Generation Carotid Artery Stent (CAS) Platform
5/1/2023
InspireMD, Inc., developer of the CGuard™ Embolic Prevention Stent System for the prevention of stroke, announced that the first carotid artery disease patient has been treated utilizing CGuard Prime, the company’s next generation CAS stent platform.
-
InspireMD to Report First Quarter 2023 Financial Results on May 9, 2023, and Provide Corporate Business Update-Conference call and webcast to be held at 8:30 a.m. EDT-
4/27/2023
InspireMD, Inc. announced it will report first quarter 2023 financial results on Tuesday, May 9th, 2023, before the financial markets open.
-
InspireMD Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update
3/30/2023
InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for treatment of carotid artery disease (CAD) and prevention of stroke today announced financial and operating results for the fourth quarter ended December 31, 2022.